Adagrasib versus docetaxel in KRAS-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.

Background: Adagrasib is a KRAS inhibitor that demonstrated promising activity against KRAS-mutated advanced non-small-cell lung cancer (NSCLC) in a phase 2 trial. Here we aimed to compare the efficacy and safety of adagrasib versus docetaxel in patients with KRAS-mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

Methods: KRYSTAL-12 is a randomised, multicentre, open-label, phase 3 trial conducted at 230 centres in 22 countries.